Literature DB >> 17224965

Clinical, histologic, and immunohistochemical evaluation of iris metastases from small cell lung carcinoma.

Letícia R Moura1, Yu F Yang, Bernadete Ayres, Oswaldo Moura Brasil, Bruno F Fernandes, Miguel N Burnier.   

Abstract

CASE REPORT: We report the case of a patient with small cell lung carcinoma who developed multiple metastases in the iris. The eye was enucleated after failure of a conservative approach. The specimen underwent histologic and immunohistochemical evaluation that confirmed the diagnosis. COMMENTS: Metastatic carcinoma is the most common form of intraocular malignancy, and breast is the most prevalent primary location, followed by lung. Small cell lung carcinoma constitutes 23.1% of lung neoplasias. It has a significantly worse prognosis than non-small cell carcinoma due to its propensity for early and widespread dissemination. Uveal metastases involve the choroid more often than the iris and ciliary body, probably because the arterial distribution is more abundant in the posterior than in the anterior uvea. Iris involvement represents only 9% of the metastatic uveal tumours.

Entities:  

Mesh:

Year:  2006        PMID: 17224965     DOI: 10.3129/i06-077

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  3 in total

1.  Intravitreal bevacizumab for iris metastasis of small-cell lung carcinoma with neovascular glaucoma.

Authors:  Chikae Nakashima; Hiroshi Keino; Takayo Watanabe; Wakako Taki; Annabelle A Okada
Journal:  Jpn J Ophthalmol       Date:  2011-02-18       Impact factor: 2.447

2.  Small-cell lung carcinoma metastasis to the iris - case presentation.

Authors:  Danuta Nikratowicz; Iwona Rospond-Kubiak; Jarosław Kocięcki
Journal:  Contemp Oncol (Pozn)       Date:  2013-06-28

3.  Iris Metastasis in a Patient With Small Cell Lung Cancer: A Case Report.

Authors:  Minas Sakellakis; Stavros Peroukides; Gregoris Iconomou; Haralabos Kalofonos
Journal:  Iran Red Crescent Med J       Date:  2016-02-13       Impact factor: 0.611

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.